Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Telitacicept delivers breakthrough proteinuria decline in Chinese IgA nephropathy phase 3 study Find out how RemeGen’s Telitacicept achieved phase 3 success in reducing proteinuria for IgA nephropathy patients in China. bySoujanya RaviNovember 8, 2025